Vaccinex logo
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
February 21, 2024 08:00 ET | Vaccinex, Inc.
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...
Stacked logo.png
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
February 15, 2024 18:35 ET | Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of...
Logo.png
GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis
December 14, 2023 03:29 ET | GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing...
Stacked logo.png
Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases
November 10, 2023 01:35 ET | Sosei Group Corporation
Tokyo, Japan, Cambridge, UK and New York, USA – 10 November 2023 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and Kallyope, a clinical stage...
Stacked logo.png
Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership
October 31, 2023 03:30 ET | Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 31 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will receive a US$3.75 million milestone payment under the 2019 multi-target...
Stacked logo.png
Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
October 31, 2023 03:00 ET | Sosei Group Corporation
NDA includes robust data from a Phase 3 trial that demonstrated efficacy of daridorexant on improving Total Sleep Time and Latency for Sleep Onset, while maintaining a favorable safety profileSosei...
Logo.png
GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100
October 26, 2023 03:33 ET | GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical stage international biopharmaceutical company with an innovative approach to developing...
Stacked logo.png
Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress
October 25, 2023 04:00 ET | Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 25 October 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Friday, 10 November 2023, at 4 pm JST. The meeting will be held...
Logo.png
GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1
October 10, 2023 03:00 ET | GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced today the expansion of its...
Salipro_logo_2lines.png
Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration
October 10, 2023 03:00 ET | Salipro Biotech AB
Salipro Biotech and Icosagen announce the initiation of a multi-target collaboration for the discovery and characterization of monoclonal antibodies